Patents by Inventor Rongfeng LAN

Rongfeng LAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10787465
    Abstract: Provided herein are lanthanide complexes that exhibit specific subcellular localization to primary cilium. The lanthanide complexes provided herein are useful for imaging, tagging, and pull down of binding targets located in primary cilium.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: September 29, 2020
    Assignee: New Life Medicine Technology Company Limited
    Inventors: Ka Leung Wong, Hongguang Li, Chi Fai Chan, Rongfeng Lan
  • Publication number: 20190127393
    Abstract: Provided herein are lanthanide complexes that exhibit specific subcellular localization to primary cilium. The lanthanide complexes provided herein are useful for imaging, tagging, and pull down of binding targets located in primary cilium.
    Type: Application
    Filed: October 31, 2018
    Publication date: May 2, 2019
    Inventors: Ka Leung WONG, Hongguang LI, Chi Fai CHAN, Rongfeng LAN
  • Patent number: 10183956
    Abstract: The present invention relates to a water-soluble, simple, stable tris(N-(tert-butyl)acetamide) cyclen-based europium complex HGEu001 which exhibits the specific subcellular localization in the primary cilium with a quantum yield as high as 10% in water and a lifetime of 0.56 ms lifetime. In particular, the present invention provides simplicity of the design and synthesis of a complex. Comprehensive studies were performed in numerous cell lines, such as HeLa, SN-K-SH and MRC5; the motif structure, HGEu002, has also been synthesized as the negative control for in vitro imaging studies. The two photon in vitro imaging were done in three dimensions to emphasize on the specific localization in primary cilium of HGEu001. This is one of the very limited examples for direct primary cilium imaging.
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: January 22, 2019
    Assignee: New Life Medicine Technology Company Limited
    Inventors: Ka Leung Wong, Hongguang Li, Chi Fai Chan, Rongfeng Lan
  • Publication number: 20170342090
    Abstract: The present invention relates to a water-soluble, simple, stable tris(N-(tert-butyl)acetamide) cyclen-based europium complex HGEu001 which exhibits the specific subcellular localization in the primary cilium with a quantum yield as high as 10% in water and a lifetime of 0.56 ms lifetime. In particular, the present invention provides simplicity of the design and synthesis of a complex. Comprehensive studies were performed in numerous cell lines, such as HeLa, SN-K-SH and MRC5; the motif structure, HGEu002, has also been synthesized as the negative control for in vitro imaging studies. The two photon in vitro imaging were done in three dimensions to emphasize on the specific localization in primary cilium of HGEu001. This is one of the very limited examples for direct primary cilium imaging.
    Type: Application
    Filed: May 25, 2017
    Publication date: November 30, 2017
    Inventors: Ka Leung WONG, Hongguang LI, Chi Fai CHAN, Rongfeng LAN
  • Patent number: 9522925
    Abstract: The present invention discloses a new modality of photodynamic therapy (PDT) through the design of the present invention's truly dual-functional—PDT and imaging—gadolinium complex (Gd—N) with a molecular formula of: which can target cancer, cells specifically. The present invention provides a PDT drug that can specifically localize on the anionic cell membrane of cancer cells in which its laser-excited photoemission signal can be monitored without triggering the phototoxic generation of reactive oxygen species—singlet oxygen—prior to due excitation. The present invention also provides the use of Gd—N as a tumor selective PDT photosensitizer modality.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: December 20, 2016
    Assignee: Hong Kong Baptist University
    Inventors: Ka-Leung Wong, Wai-Kwok Wong, Rongfeng Lan, Tao Zhang
  • Publication number: 20160130284
    Abstract: The present invention discloses a new modality of photodynamic therapy (PDT) through the design of the present invention's truly dual-functional—PDT and imaging—gadolinium complex (Gd-N) with a molecular formula of: which can target cancer, cells specifically. The present invention provides a PDT drug that can specifically localize on the anionic cell membrane of cancer cells in which its laser-excited photoemission signal can be monitored without triggering the phototoxic generation of reactive oxygen species—singlet oxygen—prior to due excitation. The present invention also provides the use of Gd-N as a tumor selective PDT photosensitizer modality.
    Type: Application
    Filed: November 5, 2015
    Publication date: May 12, 2016
    Inventors: Ka-Leung WONG, Wai-Kwok WONG, Rongfeng LAN, Tao ZHANG